PhaseBio Pharmaceuticals Inc is a leading biopharmaceutical company that focuses on developing and commercializing novel therapies to improve the lives of patients. The company values innovation, collaboration, and a patient-centric approach. PhaseBio Pharmaceuticals believes in the power of scientific discovery and uses cutting-edge technology to advance their pipeline of potential treatments. With a commitment to excellence, PhaseBio Pharmaceuticals aims to transform patient care by delivering innovative therapies and addressing unmet medical needs. Through its dedication to research and development, PhaseBio Pharmaceuticals strives to make a meaningful impact in the healthcare industry and improve the lives of patients worldwide.

PhaseBio Pharmaceuticals Inc primarily operates in the United States.

PhaseBio Pharmaceuticals Inc has achieved several significant milestones. These include the successful completion of their Phase 1 clinical trial for PB2452, a reversal agent for antiplatelet therapy, which exhibited positive results. Additionally, PhaseBio Pharmaceuticals Inc received FDA Breakthrough Therapy designation for PB2452, recognizing its potential to address life-threatening bleeding events. Another milestone was the initiation of the Phase 2 clinical trial for PB2452, which aims to further evaluate its safety and efficacy. Furthermore, PhaseBio Pharmaceuticals Inc successfully completed their Phase 2a clinical trial for PB1046, a potential treatment for pulmonary arterial hypertension. These achievements showcase the company's dedication to developing innovative therapies for various medical conditions.

PhaseBio Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing transformative therapies for rare diseases. Founded in 2002, PhaseBio is headquartered in Malvern, Pennsylvania. The company is known for its innovative approaches in developing treatments for orphan diseases. PhaseBio is committed to improving the lives of patients by combining expertise in biophysics, protein engineering, and manufacturing technology. They have a diverse pipeline of potential therapies targeting various therapeutic areas, including cardiopulmonary, metabolic, and autoimmune disorders. With a strong dedication to scientific excellence, PhaseBio Pharmaceuticals Inc continues to advance novel treatments and make significant contributions to the healthcare industry.

The main competitors of PhaseBio Pharmaceuticals Inc in the market include pharmaceutical companies such as Amgen, Inc., BioMarin Pharmaceutical Inc., and AstraZeneca PLC. They operate in the same industry and develop similar biotherapeutics and pharmaceutical products. However, PhaseBio Pharmaceuticals Inc distinguishes itself by its unique focus on developing novel treatments for cardiovascular and cardiopulmonary diseases. As a leading player in this sector, PhaseBio Pharmaceuticals Inc strives to deliver innovative solutions and contribute to the advancement of patient care within the competitive market landscape.

PhaseBio Pharmaceuticals Inc is primarily active in the biopharmaceutical industry.

The business model of PhaseBio Pharmaceuticals Inc is focused on developing and commercializing innovative treatments for patients with life-threatening orphan diseases, including cardiopulmonary and metabolic disorders. PhaseBio utilizes its proprietary elastin-like polypeptide (ELP) biopolymer technology to develop novel therapies. By targeting specific disease pathways, PhaseBio aims to address unmet medical needs and improve the lives of patients. Through strategic collaborations, PhaseBio aims to accelerate the development and commercialization of its product candidates.

PhaseBio Pharmaceuticals P/E suhe on −0,00.

PhaseBio Pharmaceuticals KUV on 0,00.

AlleAktien kvaliteediskoor ettevõttele PhaseBio Pharmaceuticals on 2/10.

oodatud PhaseBio Pharmaceuticals käive on 51,28 mln. USD.

oodatud PhaseBio Pharmaceuticals kasum on −83,20 mln. USD.

The US-American company PhaseBio Pharmaceuticals Inc is one of the leading biotech companies in the development of innovative drugs for the treatment of serious diseases such as cardiovascular diseases, kidney diseases, and rare genetic diseases. Its business model is based on developing new treatment options for patients suffering from severe diseases due to a lack of treatment options. The company relies on its proprietary technology platform that allows for the conversion of biological molecules into native peptides. This technology enables the creation of therapeutics with improved efficacy, longer duration of action, and higher bioavailability. PhaseBio's portfolio currently includes several innovative products in various clinical phases. One of the key products is PB1046, a peptide-based drug for the treatment of pulmonary arterial hypertension. PB1046 has already been approved for a phase 2 study and has shown promising results so far. Approval for PB1046 could be a breakthrough for the company. Another promising product is PB2452, a specific antidote for the blood thinner Ticagrelor. PB2452 can be used in patients taking Ticagrelor for the prevention of heart attacks or strokes to quickly neutralize the drug's effects. This can save lives in emergencies and provide doctors with better control over the risk of bleeding. In addition to these two main products, the company is working on other promising treatments such as PB1046 for the treatment of heart failure and several preclinical programs for the treatment of rare diseases. PhaseBio works closely with various partners and investors to bring its products to market. One important partner is the pharmaceutical company SFJ Pharmaceuticals, which supports the financing of ongoing clinical trials and the marketing of products in Asia and other parts of the world. PhaseBio's business model is based on the development of innovative drugs with high medical needs and a large market. By leveraging its proprietary technologies and working with experienced partners and investors, the company aims for sustainable value creation and strives for a leading position in the biotech industry.

PhaseBio Pharmaceuticals maksab dividendi 0 USD, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu PhaseBio Pharmaceuticals jaoks arvutada või ettevõte ei maksa dividende välja.

PhaseBio Pharmaceuticals ISIN on US7172241090.

PhaseBio Pharmaceuticals WKN on A2N7LU.

PhaseBio Pharmaceuticals tähis on PHASQ.

Viimase 12 kuu jooksul maksis PhaseBio Pharmaceuticals dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab PhaseBio Pharmaceuticals tõenäoliselt dividendi summas 0 USD.

PhaseBio Pharmaceuticals praegune dividenditootlus on .

PhaseBio Pharmaceuticals maksab kvartaalset dividendi. See makstakse välja kuudel .

PhaseBio Pharmaceuticals maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 USD. See vastab dividenditootlusele 0 %.

PhaseBio Pharmaceuticals on liigitatud sektorisse 'Tervis'.

Viimase PhaseBio Pharmaceuticals dividendide saamiseks 12.7.2024 suuruses 0 USD pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 12.7.2024.

Viimane dividendimakse toimus 12.7.2024.

Aastal 2023 maksis PhaseBio Pharmaceuticals 0 USD dividende.

PhaseBio Pharmaceuticals dividendid makstakse välja USD.